CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 2057-A |

# Specialty Guideline Management Vimizim

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Vimizim | elosulfase alfa |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications1

Vimizim is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA, Morquio A syndrome).

All other indications are considered experimental/investigational and not medically necessary.

## Documentation

Submission of the following information is necessary to initiate the prior authorization review:

* Initial requests: N-acetylgalactosamine-6-sulfatase enzyme assay or genetic testing results supporting diagnosis.
* Continuation requests: chart notes documenting a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.

## Prescriber Specialties

This medication must be prescribed by or in consultation with a physician who specializes in the treatment of metabolic disease and/or lysosomal storage disorders.

## Coverage Criteria

### Mucopolysaccharidosis IVA (MPS IVA, Morquio A syndrome)1,2

Authorization of 12 months may be granted for treatment of MPS IVA (Morquio A syndrome) when the diagnosis of MPS IVA was confirmed by enzyme assay demonstrating a deficiency of N-acetylgalactosamine-6-sulfatase enzyme activity or by genetic testing.

## Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the Coverage Criteria section who have a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.

## References

1. Vimizim [package insert]. Novato, CA: BioMarin Pharmaceutical Inc.; December 2019.
2. Hendriksz CJ, Berger KI, Giugliani R, et al. International guidelines for the management and treatment of Morquio A syndrome. Am J Med Genet A. 2015;167A(1):11-25.